Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease
← catalyst calendarSponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 2
Status
Withdrawn
Study type
Interventional
Design
Na · None · Prevention
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study was withdrawn after the Marburg outbreak in Rwanda was declared over, prior to enrollment of any participants.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Dec 2025 | estimated | When the study began enrolling |
| Primary completion | Dec 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Filovirus Disease
- Postexposure Prophylaxis for Filovirus Disease
Intervention
- Drug: obeldesivir — also filed as GS-5245
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants Experiencing Serious Adverse Events (SAEs)
measured First dose date up to 29 Days
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed